RINVOQ Beats Humira in RA Head-to-Head Trial

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP<2.6) at week 121SELECT-SWITCH is the first Phase 3b/4 head-to-head

RINVOQ beats Humira in RA head-to-head trial

AbbVie has been staging a generational handoff for years: as Humira’s U.S. exclusivity fell and biosimilars swarmed, the company groomed Rinvoq and Skyrizi as the next standard-bearers. Investors already know the script: AbbVie has guided the duo to more than $31 billion in combined sales by 2027, and Humira’s 2022 global peak north of $21… The post AbbVie’s RINVOQ showed superiority over HUMIRA in rheumatoid arthritis study appeared first on Dr…

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor - Life Sciences British Columbia

NORTH CHICAGO, Ill. - AbbVie announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study